Richard Hoffman
Ophthalmology · Eugene, ORNPI 1356340210
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,400 of the $17,150 with a category attached, or 78.1%. Microsurgical Technology, Inc. accounts for 70.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $12,277 and has fallen 98.4% since, to $194 in 2025. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $244.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$12K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Alcon Research LLC$1K
- Amgen$230
- AbbVie$159
- Sun Pharmaceutical Industries Inc.$156
- plus $670 from 15 others
What the payments were for
- Consulting fees$13,40078%
- Speaking & faculty fees$1,5009%
- Travel & lodging$7684%
- Food & beverage$1,4829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 1 | $12,000 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $2,534 |
| Alcon Research LLC | 1 | $1,400 |
| Amgen(2 entities) | 9 | $230 |
| AbbVie(2 entities) | 10 | $159 |
| Sun Pharmaceutical Industries Inc. | 8 | $156 |
| Oyster Point Pharma, Inc. | 5 | $114 |
| Bausch & Lomb Americas Inc. | 5 | $111 |
| Alcon | 3 | $64 |
| Tarsus Pharmaceuticals, Inc. | 3 | $51 |
| Dompe US, Inc. | 3 | $50 |
| Carl Zeiss Meditec, Inc. | 1 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $42 |
| NEW World Medical,inc. | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $28 |
| Biotissue Holdings Inc. | 1 | $26 |
| Coopervision Inc. | 1 | $25 |
| Heidelberg Engineering, Inc. | 1 | $24 |
| Iridex Corporation | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$1,400
- VERITAS Vision System$114
How this compares
$17,150 in reported general payments places this provider in the 95th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $34,604 |
| Prednisolone Acetate | 721 | $26,794 |
| XiidraLifitegrast | 15 | $18,542 |
| LumiganBimatoprost | 17 | $12,592 |
| Cyclosporine | 20 | $11,114 |
| Latanoprost | 627 | $8,565 |
| Timolol Maleate | 634 | $8,286 |
| Ketorolac Tromethamine | 363 | $7,036 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $6,448 |
| Loteprednol Etabonate | 43 | $6,085 |
| VyzultaLatanoprostene Bunod | 12 | $5,766 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $5,658 |
| Brimonidine Tartrate | 232 | $5,537 |
| RhopressaNetarsudil Mesylate | 15 | $4,625 |
| Ofloxacin | 353 | $3,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $159 | $52,85360 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $111 | $24,30827 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $18 | $9,82158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Eugene
- Balamurali AmbatiEugene$19K
- Eric NiespodzonyEugene$10K
- Justin EtzelEugene$6K
- Jason GrossEugene$6K
- John HainesEugene$6K
- Joseph MandoEugene$4K
- Shelley JelineoEugene$4K
- Robert BeardsleyEugene$4K
- Kent KarrenEugene$4K
- Brian WalkerEugene$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.